e.g. mhealth
Search Results (1 to 6 of 6 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 4 JMIR Research Protocols
- 1 JMIR Medical Informatics
- 1 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 JMIR Formative Research
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Go back to the top of the page Skip and go to footer section
Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study
Third, pharmacokinetics is another focus of TKIs research. Optimization and selectivity study is an important direction for continuing clinical trials after the launch of many TKIs. Besides, individualized blood concentration monitoring is important for patients with poor efficacy or severe side effects [38].
In recent years, TKIs have been widely used for tumor-targeted therapies.
JMIR Med Inform 2022;10(4):e34548
Download Citation: END BibTex RIS
However, pilot studies need to precede interventional studies to understand feasibility and to glean important information about the pharmacokinetics of cannabis in the pediatric patient population to guide dosing strategies.
While the small sample size of this pilot study will preclude treatment recommendations, the importance of this study should not be understated.
JMIR Res Protoc 2021;10(10):e31281
Download Citation: END BibTex RIS
It ended in March 2021 for the medication adherence part but is ongoing until December 2021 for the pharmacokinetics part.
Oncologists were asked to refer eligible patients to a pharmacist Ph D student or to the research staff from the Center of Experimental Therapeutics (CHUV), who will present the informed consent form to the patient after the medical visit. The participants will follow their treatment as usual, and no changes in the usual medical procedure will be made.
JMIR Res Protoc 2021;10(6):e30090
Download Citation: END BibTex RIS
We will determine plasma levonorgestrel pharmacokinetics after a single dose of norgestrel 75 mcg, at steady state, and after a delayed intake and after a missed pill. We will assess the safety of norgestrel 75 mcg taken daily for 12 weeks (SAE/AEs, bleeding patterns, abnormal blood chemistry or blood count parameters).
Data will be prospectively collected and entered into a secure, centralized, electronic data capture system as soon as possible after the information is collected.
JMIR Res Protoc 2021;10(6):e29208
Download Citation: END BibTex RIS
Since the highest dose of ivermectin used in humans that was tested and found to be well tolerated and safe is 2000 mcg/kg given as a single dose, this provides a large margin of safety allowing for inter-individual variation of pharmacokinetics. The middle group was chosen at 50% of the highest dose to allow for a dose response in terms of tolerance and efficacy.
Using existing literature data [24,35] we developed a pharmacokinetic model for ivermectin in humans.
JMIR Res Protoc 2016;5(4):e213
Download Citation: END BibTex RIS